Urinary tract infections (UTIs) are a global health concern exacerbated by rising antimicrobial resistance (AMR), especially in developing countries where empirical therapy is common. Untreated UTIs can progress to sepsis with a poor prognosis. Understanding local AMR profiles of uropathogens is crucial for effective UTI treatment. This study aimed to identify the predominant uropathogens and determine their AMR profiles against a range of commonly used antimicrobials. This study was a 5-year retrospective cross-sectional surveillance study conducted on urine cultures processed from January 1, 2020 to December 31, 2024 at the University Teaching Hospital of Kigali. In total, 2,921 positive urine cultures and their antimicrobial susceptibility testing results were recorded and analyzed by pathogen and across care settings. Descriptive statistics were used to summarize the data. Associations were evaluated at a 5% significance level. This study found that among 2,921 isolates, Escherichia coli (64%) and Klebsiella pneumoniae (22.9%) were the predominant uropathogens. High resistance rates were observed against commonly used antibiotics, such as amoxicillin-clavulanic acid (>88%), third-generation cephalosporins (51-75%), and fluoroquinolones (∼55%) in both species, with K. pneumoniae showing a more extensive resistance profile. Conversely, the isolates were less resistant to carbapenems (imipenem and meropenem) and amikacin (<20%) across care settings. The findings reveal a significant burden of multidrug-resistant gram-negative pathogens at the University Teaching Hospital of Kigali, underscoring the urgent need for enhanced antimicrobial stewardship and sustained surveillance. Such measures are essential to preserve the efficacy of critical antibiotics, particularly carbapenems and aminoglycosides, and to guide effective clinical management.
Munyemana et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: